Pan-cancer

Quest solid tumor solutions combine state-of-the-art solid tumor genetic sequencing with powerful data analysis to provide a wide range of highly personalized information to help inform diagnosis and treatment.

• A broad oncology test menu available, including pan-tumor and cancer-specific panels
• Comprehensive health plan coverage to help reduce patient financial responsibility
• Easy access to Quest oncology experts for consultation and results interpretation

• Block retrieval program for when the sample is not on hand
• Prior authorization and patient financial assistance programs available
• Dedicated customer service team available at 1.833.710.0351

LiquidSEQ™ is a liquid biopsy for treatment selection. It provides a comprehensive molecular profile—including 523 genes associated with a broad spectrum of solid tumor cancers—that assesses the DNA only for single nucleotide variants (SNVs), copy number variants (CNVs), and fusions along with genomic signatures, microsatellite instability (MSI), and tumor mutation burden (TMB). This panel would be used if the clinician desires a comprehensive analysis of a patient’s genetic profile from the patient’s blood in the event tissue is not available or insufficient. This panel contains clinically actionable genes as well as emerging genes.

Precision medicine is an emerging approach for disease prevention and treatment that takes individual variability into account. This next-generation sequencing (NGS) panel, along with the computational resources and tools that process and analyze the data, allows the characterization of individual patients and tumor types. Guidelines exist for using results from many of these genes for selection of FDA-approved therapies.

Solid TumorSEQ™ provides a comprehensive molecular profile from biopsy tissue, including 523 genes associated with a broad spectrum of solid tumor cancers, and assesses the DNA and RNA for SNVs, CNVs, fusions, and splice variants along with genomic signatures, microsatellite instability (MSI), and tumor mutation burden (TMB). This panel would be used if a clinician desires a comprehensive analysis of a patient’s genetic profile from tumor tissue. This panel contains clinically actionable genes as well as emerging genes chosen based on alignment to guidelines, drug labels and clinical trials across multiple solid tumor types.

DPYD genotype testing supports you and your patients by contributing to patient safety initiatives, enhancing cost control, and delivering more optimal patient outcomes.

• Helping reduce severe and avoidable adverse events to Fluorouracil (5-FU)–based chemotherapy regimens
• Offering a simple, 1-time, targeted germline test with a person’s entire life cycle regardless of cancer type or staging
• Potentially reducing downstream costs associated with hospitalizations, ICU stays, and treatment delays
• Helping support your precision oncology initiatives through pharmacogenomics

Genetics can play a significant role in the selection of certain medications. For instance, individuals may metabolize medications too quickly or too slowly. This test analyzes genes of known pharmacogenomic value, allowing clinicians to gain valuable insight into an individual’s response to, and adverse effects from, medications with known gene-drug interactions.

Sensitivity matters when looking for the smallest evidence of disease, such as residual disease after surgery or response to adjuvant chemotherapy. Haystack MRD^® minimizes false negatives by detecting ultralow levels of ctDNA, providing confidence in therapeutic decisions.¹